Epithelial-mesenchymal transition-like phenotypic changes of retinal pigment epithelium induced by TGF-γ Are prevented by PPAR-γ agonists

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 11, 2012, Pages 6955-6963

  Hatanaka, Hiroki ^a   Koizumi, Noriko ^b   Okumura, Naoki ^a,b   Kay, EunDuck P ^b,c   Mizuhara, Eri ^b   Hamuro, Junji ^a   Kinoshita, Shigeru ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b DOSHISHA UNIVERSITY   (Japan)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALPHA SMOOTH MUSCLE ACTIN; FIBRONECTIN; NERVE CELL ADHESION MOLECULE; PHALLOIDIN; PIOGLITAZONE; PROTEIN ZO1; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CIS TRANS ISOMERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID ISOMEROHYDROLASE; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL CELL; ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; CYTOSKELETON; EPITHELIAL MESENCHYMAL TRANSITION; HAPLORHINI; IMMUNOCYTOCHEMISTRY; NONHUMAN; PHASE CONTRAST MICROSCOPY; PHENOTYPE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CELL SHAPE; DRUG EFFECT; DRUG POTENTIATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MACACA FASCICULARIS; METABOLISM; PHOSPHORYLATION;

ANIMALS; BLOTTING, WESTERN; CELL SHAPE; CELLS, CULTURED; CIS-TRANS-ISOMERASES; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; MACACA FASCICULARIS; MICROSCOPY, PHASE-CONTRAST; PHENOTYPE; PHOSPHORYLATION; PPAR GAMMA; RETINAL PIGMENT EPITHELIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMAD2 PROTEIN; SMAD3 PROTEIN; SODIUM-POTASSIUM-EXCHANGING ATPASE; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA2; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84872026309     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10488     Document Type: Article

References (41)

1. Fong DS, Aiello L, Gardner TW, et al. Diabetic retinopathy. Diabetes Care. 2003;26(suppl 1);S99-S102.
2. Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002; 21:127-144.
3. Richter-Mueksch S, Stur M, Stifter E, Radner W. Differences in reading performance of patients with drusen maculopathy and subretinal fibrosis after CNV. Graefes Arch Clin Exp Ophthalmol. 2006;244:154-162.
4. Unver YB, Yavuz GA, Bekiroglu N, Presti P, Li W, Sinclair SH. Relationships between clinical measures of visual function and anatomic changes associated with bevacizumab treatment for choroidal neovascularization in age-related macular degeneration. Eye (Lond). 2009;23:453-460.
5. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366:1227-1239.
6. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43:3-18.
7. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest. 2002;110:341-350.
8. Schnaper HW, Hayashida T, Hubchak SC, Poncelet AC. TGFbeta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol. 2003;284:F243-F252.
9. Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 2007;293:L525-L534.
10. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci. 2002;7:d793-d807.
11. Piek E, Moustakas A, Kurisaki A, Heldin CH, ten Dijke P. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci. 1999;112(Pt 24):4557-4568.
12. Valcourt U, Kowanetz M, Niimi H, Heldin CH, Moustakas A. TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell. 2005;16:1987-2002.
13. Kawai T, Masaki T, Doi S, et al. PPAR-gamma; agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest. 2009;89:47-58.
14. Higashi K, Oda T, Kushiyama T, et al. Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. Nephrology (Carlton). 2010;15:327-335.
15. Galli A, Crabb DW, Ceni E, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology. 2002;122: 1924-1940.
16. Aoki Y, Maeno T, Aoyagi K, et al. Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis. Respiration. 2009;77:311-319.
17. Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol. 2009;174:519-533.
18. Shiomi T, Tsutsui H, Hayashidani S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;106: 3126-3132.
19. Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol. 2003;23:532-543.
20. Hills CE, Squires PE. TGF-beta;1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol. 2010;31:68-74.
21. Hill C, Flyvbjerg A, Gronbaek H, et al. The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology. 2000;141:1196-1208.
22. Cheng J, Grande JP. Transforming growth factor-beta signal transduction and progressive renal disease. Exp Biol Med (Maywood). 2002;227:943-956.
23. Connor TB Jr, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest. 1989;83:1661-1666.
24. Hirase K, Ikeda T, Sotozono C, Nishida K, Sawa H, Kinoshita S. Transforming growth factor beta2 in the vitreous in proliferative diabetic retinopathy. Arch Ophthalmol. 1998;116:738-741.
25. Bochaton-Piallat ML, Kapetanios AD, Donati G, Redard M, Gabbiani G, Pournaras CJ. TGF-beta1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy. Invest Ophthalmol Vis Sci. 2000;41:2336-2342.
26. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res. 1996;62:155-169.
27. Kimoto K, Nakatsuka K, Matsuo N, Yoshioka H. p38 MAPK mediates the expression of type I collagen induced by TGF beta2 in human retinal pigment epithelial cells ARPE-19. Invest Ophthalmol Vis Sci. 2004;45:2431-2437.
28. Maminishkis A, Chen S, Jalickee S, et al. Confluent monolayers of cultured human fetal retinal pigment epithelium exhibit morphology and physiology of native tissue. Invest Ophthalmol Vis Sci. 2006;47:3612-3624.
29. Parapuram SK, Chang B, Li L, et al. Differential effects of TGFbeta and vitreous on the transformation of retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2009;50:5965-5974.
30. Oberstein SY, Byun J, Herrera D, Chapin EA, Fisher SK, Lewis GP. Cell proliferation in human epiretinal membranes: characterization of cell types and correlation with disease condition and duration. Mol Vis. 2011;17:1794-1805.
31. Saika S, Yamanaka O, Ikeda K, et al. Inhibition of p38MAP kinase suppresses fibrotic reaction of retinal pigment epithelial cells. Lab Invest. 2005;85:838-850.
32. Casaroli-Marano RP, Pagan R, Vilaro S. Epithelial-mesenchymal transition in proliferative vitreoretinopathy: intermediate filament protein expression in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1999;40:2062-2072.
33. Cheng HC, Ho TC, Chen SL, Lai HY, Hong KF, Tsao YP. Troglitazone suppresses transforming growth factor beta-mediated fibrogenesis in retinal pigment epithelial cells. Mol Vis. 2008;14:95-104.
34. Pan H, Chen J, Xu J, Chen M, Ma R. Antifibrotic effect by activation of peroxisome proliferator-activated receptor-gamma in corneal fibroblasts. Mol Vis. 2009;15:2279-2286.
35. Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007;98:1512-1520.
36. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005;24:5764-5774.
37. Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-tomesenchymal transition. EMBO J. 2004;23:1155-1165.
38. Masszi A, Fan L, Rosivall L, et al. Integrity of cell-cell contacts is a critical regulator of TGF-beta 1-induced epithelial-to-myofibroblast transition: role for beta-catenin. Am J Pathol. 2004; 165:1955-1967.
39. Huber MA, Azoitei N, Baumann B, et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004;114: 569-581.
40. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem. 2000; 275:36803-36810.
41. Burch ML, Zheng W, Little PJ. Smad linker region phosphorylation in the regulation of extracellular matrix synthesis. Cell Mol Life Sci. 2011;68:97-107.